 |
Medical Technology Platform |
The following outlines information relevant to the development
pipeline for our various
Medical Technologies. For a more general overview
of our medical capabilities, please
click here.General OverviewOur aim is to serve the concerns of both consumers and the industry alike. As such, it is our goal is to produce products and services that will better serve, as a whole and in a highly productive and positive manner, both the biotechnology industry and the general health needs of the human race. The discovery and development of our various medical technologies is something that was inevitable with both the ongoing deciphering of the human genome and the general investigations into the use of nutritional supplements. And, nonetheless, pharmaceutical products and many other biotechnologies will still have important roles to play – especially in cases of certain emergency situations and certain surgical procedures as well as for severe cases where an 'extra edge' is required – and many great new advances in pharmaceuticals and many other types of biotechnologies will be able to evolve from our new breakthrough understandings, thus resulting in even more major benefits for both consumer and producer alike. It is important to note that our discoveries can actually be incorporated into the main research and development processes involved with just about any other type of medical science so as to greatly refine and enhance these processes for much faster, more reliable and more highly defined results. In fact, with ongoing research and development it is highly envisaged that numerous highly extensive breakthroughs and general developments will eventuate relative to many varied industry sectors, including very specific industry sectors and application areas that are currently under-established and/or underutilised. Having said all of this, it is also important to note that our medical technologies relate directly to both known and accepted fields of science as well as newly evolving fields of expertise that are in their infancy. Intellectual Property ProtectionAt present no patents or provisional applications have been filed. However, all patent protectable intellectual property is owned solely by BC Biogenics Pty Ltd. It is important to be fully aware that, due to the enormity and complexity of our medical technologies and their numerous applications, there are already and will continue to be many patents to be filed. Having said this, please do consider the fact that this simply helps to show just how much there is to gain by being involved with any of our medical technologies…! Furthermore, before any patents can be filed there is still some primary 'ground work' that needs to be conducted so as to establish a strong IP position that will not come undone or be threatened in any way by patent oppositions and the like. It is also important to note that we have conducted extensive research in the quest to develop what we have established and in this process we have not been able to find any patents or publications that give definitive details to the same extent or matching of what we have established. Overview Of The OpportunityInitially and most predominantly we are seeking to continue completing the primary ground work that is required to secure a very strong IP position. This will mostly entail completing the full mapping of our newly discovered metabolic networks. We will then be looking to fully apply to our metabolic amplification platform technology not only our newly discovered metabolic networks but also the interrelated new understandings of metabolism and our new delivery system. It is important to note that the underpinnings of our metabolic amplification platform technology will foster an explosion of new and highly focused research and development that will, in turn, also foster an explosion of both new and more highly evolved knowledge and capabilities in most all fields of medical science and biotechnology in general. Our new breakthrough discoveries and understandings are truly going to change the face of both the nutritional supplements industry and the medical industry as a whole! Utilising our overall new knowledge, not only can we now make nutritional supplements work just as good as, and in many instances even better than, that of pharmaceutical substances but long term ongoing treatment after the relevant conditions have been rectified can result in biological and genetic changes which protect against medical conditions reoccurring as well as from related new conditions occurring. Furthermore to this, the treatments and general product concepts we are developing can also be utilised as straight forward nutritional supplement products which will serve to prevent medical conditions from occurring in the first place or, at least, dramatically reducing the incidence rates of severe illness, which, in turn, will still be treated with additional products/services and/or simply higher dosage rates as required. These factors should result in quite substantial and ongoing sales volumes, even if people are not getting as sick and as often as current trends are denoting. This is especially true considering that the incidence rates for most all illnesses are on the increase signifying that most all people are not willing to make the necessary lifestyle changes that are required for good health through healthy eating and other healthy lifestyle traits but also because of the global growth rate of the use and acceptance of nutritional supplements for all matters of health. And, having said all of this, our already established vast array of findings and developments coupled with continuous ongoing research and development will surely help to ensure that BC Biogenics Pty Ltd and any industry partners that eventuate remain at the forefront of this new technological era and thus also be able to maintain a commercial dominion over it for many decades to come. Something you truly need to understand is that the core of our medical technologies permeates most all of the human genome – as discussed here in the section on We Are But Mere Computer-Like Biological Machines. As such, what we are talking about here is not some mere single or simple technology that fills 1 or maybe even 2 or 3 niche industry needs but instead a whole new understanding of the human body that will have numerous impacts on most all of the life sciences industry. Our breakthroughs have the potential to be very far reaching, especially with the current global growth rate of the nutraceutical, phytoceutical and zooceutical markets and the consumer desire for such to be properly incorporated into common everyday medicinal and general health therapies, whether it be in replacement of such or complementary to such. Lastly, it is also important to note that both the time frames and the costs associated with fully developing all treatments to commercial rollout (as well as that of many of the other new technologies that will evolve) should be substantially reduced due to our new knowledge of how to both inhibit/minimise side effects as well as how to actually develop products and services based on specific programmed and programmable genetic attributes. Approximated CostsPrimary: Patent and general IP strategy development: $20-30,000 National & international filing of primary platform patents: $2,500,000 Secondary: Further strategy development and implementation: $40-60,000 Implementation of initial licensing and/or joint venture strategies: $150,000 We are also open to funding from industry partners and others who would like to establish full scale operations in relation to any of the various applications of our medical technologies . As such, industry partners and others are being sought in order to further research the new pathway systems and to produce various patent protectable viable commercial outcomes, examples of which include:
With such as vast array of applications, it is both plain to see and extremely important to note that our breakthrough new discoveries and understandings will not only become the new primary underlying basis for just about all other platforms (and many other biotechnologies in general) but will also become the primary assessment tool for just about any other future biotechnology related developments before any such investigations are to proceed past the initial concept stage. Due to the enormity of the project as a whole various consultants we have sought advice from have advised that the platform technology is best suited for licensing and/or joint ventures and/or other similar arrangements with well established companies that have the appropriate and relevant resources for each of their specific industry sectors at their ready disposal. As such, we also require a person, firm or group of firms that can help us breakup the core of the overall project into its specific applications for each of the numerous industry sectors it can be applied to and then seek to license and/or negotiate joint ventures and/or whatever other kind of appropriate arrangements with appropriate companies and other commercial avenues relative to each industry sector. Having said all of this, potential means are being explored in order to procure the people and/or organisations and/or other potential means that are properly suited to provide the assistance that we require. However, if the quite large sums of money that will be required to either partially or fully develop and commercialise some or all arms of the project as a whole are solely achievable then we will alter our activities to fully develop and commercialise those aspects of the project entirely in-house. It is for these reasons, and the fact that the underpinnings of our medical technologies can be utilised in so many different sectors of the industry, that we are very open to partnering with well positioned and suited companies that compliment our medical technologies. Further Discussion & NegotiationWe are actively seeking both industry partners and others to help us further develop and commercialise the numerous technological applications of our breakthrough medical capabilities. If you would be interested in exploring our project further in relation to any potential consultancy, partnering or other commercial arrangements with us, documentation outlining the technological intellectual property in question can be provided upon the signing of a confidentiality agreement. This documentation includes things such as: a full overview of the new understandings and how the primary platform works as a whole; examples of newly discovered pathway networks and how they interact both with each other and with already known networks; examples of therapeutic end products and their novel methods of application – including examples of case studies we have conducted; examples of novel methods of cell receptor targeting and cell receptor manipulation; example substance assessments showing new insight into their true metabolic nature; and much more. As such, all of this will serve to give you a thorough understanding of this executive summary. If you would like to discuss a partnering or other opportunity with us please feel free to contact us. For more general information about partnering with us and licensing any of our technologies, please click here. |
|
| .......................................... | |
| Members Area | |
| Retrieve Password | |
| Menu | |
 |
Introduction |
|
|
Medical Technology Platform |
|
|
Seed Vitalisation Technology |
|
|
Meat Vitalisation Technology |
|
|
Potentiated Electrolysis |
|
|
Advanced Hydrocolloids |
|
|
Our Publications and Related Products & Services |
|
|
Magnetic Propulsion Drive |
|
|
Partnering With Us |
|
|
Contact Us |